Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Retatrutide is a key part of Eli Lilly's drug pipeline that could help the company maintain its dominance in the blockbuster weight loss and diabetes ... GIP and glucagon. That appears to have ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...